pBabe K-Ras 12V Citations (19)

Originally described in: Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation.
Khosravi-Far R, White MA, Westwick JK, Solski PA, Chrzanowska-Wodnicka M, Van Aelst L, Wigler MH, Der CJ Mol Cell Biol. 1996 Jul . 16(7):3923-33. PubMed

---

Articles Citing pBabe K-Ras 12V

Articles
Akt1 deletion prevents lung tumorigenesis by mutant K-ras. Hollander MC, Maier CR, Hobbs EA, Ashmore AR, Linnoila RI, Dennis PA. Oncogene. 2011 Apr 14;30(15):1812-21. doi: 10.1038/onc.2010.556. Epub 2011 Jan 17. PubMed
Modeling sarcomagenesis using multipotent mesenchymal stem cells. Rodriguez R, Rubio R, Menendez P. Cell Res. 2012 Jan;22(1):62-77. doi: 10.1038/cr.2011.157. Epub 2011 Sep 20. PubMed
LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumorigenesis through a pro-invasive genetic program. Mao XG, Hutt-Cabezas M, Orr BA, Weingart M, Taylor I, Rajan AK, Odia Y, Kahlert U, Maciaczyk J, Nikkhah G, Eberhart CG, Raabe EH. Oncotarget. 2013 Jul;4(7):1050-64. PubMed
A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice. Hu Y, Zheng M, Gali R, Tian Z, Topal Gorgun G, Munshi NC, Mitsiades CS, Anderson KC. Blood Cancer J. 2013 Nov 1;3:e156. doi: 10.1038/bcj.2013.53. PubMed
A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype. Serra RW, Fang M, Park SM, Hutchinson L, Green MR. Elife. 2014 Mar 12;3:e02313. doi: 10.7554/eLife.02313. PubMed
Characterization of rare transforming KRAS mutations in sporadic colorectal cancer. Tong JH, Lung RW, Sin FM, Law PP, Kang W, Chan AW, Ma BB, Mak TW, Ng SS, To KF. Cancer Biol Ther. 2014 Jun 1;15(6):768-76. doi: 10.4161/cbt.28550. Epub 2014 Mar 18. PubMed
KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells. Leiser D, Medova M, Mikami K, Nisa L, Stroka D, Blaukat A, Bladt F, Aebersold DM, Zimmer Y. Mol Oncol. 2015 Apr 14. pii: S1574-7891(15)00089-7. doi: 10.1016/j.molonc.2015.04.001. PubMed
Oncolytic reovirus induces intracellular redistribution of Ras to promote apoptosis and progeny virus release. Garant KA, Shmulevitz M, Pan L, Daigle RM, Ahn DG, Gujar SA, Lee PW. Oncogene. 2015 May 11. doi: 10.1038/onc.2015.136. PubMed
Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. Unni AM, Lockwood WW, Zejnullahu K, Lee-Lin SQ, Varmus H. Elife. 2015 Jun 5;4:e06907. doi: 10.7554/eLife.06907. PubMed
Simultaneous Inhibition of EGFR/VEGFR and Cyclooxygenase-2 Targets Stemness-Related Pathways in Colorectal Cancer Cells. Valverde A, Penarando J, Canas A, Lopez-Sanchez LM, Conde F, Hernandez V, Peralbo E, Lopez-Pedrera C, de la Haba-Rodriguez J, Aranda E, Rodriguez-Ariza A. PLoS One. 2015 Jun 24;10(6):e0131363. doi: 10.1371/journal.pone.0131363. eCollection 2015. PubMed
Constitutively active RAS signaling reduces 1,25 dihydroxyvitamin D-mediated gene transcription in intestinal epithelial cells by reducing vitamin D receptor expression. DeSmet ML, Fleet JC. J Steroid Biochem Mol Biol. 2017 Jan 16. pii: S0960-0760(17)30008-0. doi: 10.1016/j.jsbmb.2017.01.008. PubMed
The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-beta- catenin signaling axis. Valverde A, Penarando J, Canas A, Lopez-Sanchez LM, Conde F, Guil-Luna S, Hernandez V, Villar C, Morales-Estevez C, de la Haba-Rodriguez J, Aranda E, Rodriguez-Ariza A. Oncotarget. 2017 Mar 28;8(13):21754-21769. doi: 10.18632/oncotarget.15567. PubMed
A Role for The ATP7A Copper Transporter in Tumorigenesis and Cisplatin Resistance. Zhu S, Shanbhag V, Wang Y, Lee J, Petris M. J Cancer. 2017 Jul 5;8(11):1952-1958. doi: 10.7150/jca.19029. eCollection 2017. PubMed
Structural centrosome aberrations promote non-cell-autonomous invasiveness. Ganier O, Schnerch D, Oertle P, Lim RY, Plodinec M, Nigg EA. EMBO J. 2018 May 2;37(9). pii: embj.201798576. doi: 10.15252/embj.201798576. Epub 2018 Mar 22. PubMed
Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS(G12C)-Driven Mouse Model of Lung Cancer. Li S, Liu S, Deng J, Akbay EA, Hai J, Ambrogio C, Zhang L, Zhou F, Jenkins RW, Adeegbe DO, Gao P, Wang X, Paweletz CP, Herter-Sprie GS, Chen T, Gutierrez-Quiceno L, Zhang Y, Merlino AA, Quinn MM, Zeng Y, Yu X, Liu Y, Fan L, Aguirre AJ, Barbie DA, Yi X, Wong KK. Clin Cancer Res. 2018 Oct 1;24(19):4854-4864. doi: 10.1158/1078-0432.CCR-17-3438. Epub 2018 Jun 26. PubMed
T-Cell Deletion of MyD88 Connects IL17 and IkappaBzeta to RAS Oncogenesis. Cataisson C, Salcedo R, Michalowski AM, Klosterman M, Naik S, Li L, Pan MJ, Sweet A, Chen JQ, Kostecka LG, Karwan M, Smith L, Dai RM, Stewart CA, Lyakh L, Hsieh WT, Khan A, Yang H, Lee M, Trinchieri G, Yuspa SH. Mol Cancer Res. 2019 Aug;17(8):1759-1773. doi: 10.1158/1541-7786.MCR-19-0227. Epub 2019 Jun 4. PubMed
Kras/ADAM17-Dependent Jag1-ICD Reverse Signaling Sustains Colorectal Cancer Progression and Chemoresistance. Pelullo M, Nardozza F, Zema S, Quaranta R, Nicoletti C, Besharat ZM, Felli MP, Cerbelli B, d'Amati G, Palermo R, Capalbo C, Talora C, Di Marcotullio L, Giannini G, Checquolo S, Screpanti I, Bellavia D. Cancer Res. 2019 Nov 1;79(21):5575-5586. doi: 10.1158/0008-5472.CAN-19-0145. Epub 2019 Sep 10. PubMed
SRPK1/2 and PP1alpha exert opposite functions by modulating SRSF1-guided MKNK2 alternative splicing in colon adenocarcinoma. Liu H, Gong Z, Li K, Zhang Q, Xu Z, Xu Y. J Exp Clin Cancer Res. 2021 Feb 18;40(1):75. doi: 10.1186/s13046-021-01877-y. PubMed
FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung. Tomoshige K, Stuart WD, Fink-Baldauf IM, Ito M, Tsuchiya T, Nagayasu T, Yamatsuji T, Okada M, Fukazawa T, Guo M, Maeda Y. Cancer Res. 2023 May 2;83(9):1443-1458. doi: 10.1158/0008-5472.CAN-22-2805. PubMed

If you have published an article using this material, please email us at to have your article added to this page.